Systemic Expression of Vascular Endothelial Growth Factor in Patients with Cerebral Cavernous Malformation Treated by Stereotactic Radiosurgery.
10.3340/jkns.2016.59.5.442
- Author:
Sang Jin PARK
1
;
Seong Hyun PARK
Author Information
1. Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea. nsdoctor@naver.com
- Publication Type:Original Article
- Keywords:
Cavernous malformation;
Gamma Knife;
Stereotactic radiosurgery;
Vascular endothelial growth factor
- MeSH:
Angiogenesis Inducing Agents;
Enzyme-Linked Immunosorbent Assay;
Follow-Up Studies;
Healthy Volunteers;
Hemangioma, Cavernous, Central Nervous System*;
Humans;
Plasma;
Radiosurgery*;
Vascular Endothelial Growth Factor A*
- From:Journal of Korean Neurosurgical Society
2016;59(5):442-448
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Increased expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), is associated with the pathogenesis of cerebral cavernous malformations (CCMs). The purpose of this study was to investigate plasma levels of VEGF in normal subjects and in patients with CCM and to evaluate change in these levels following stereotactic radiosurgery (SRS). METHODS: Peripheral venous blood was collected from 6 patients with CCM before SRS using Gamma Knife and at the 1 week, 1 month, 3month, and 6 month follow-up visits. Plasma VEGF levels were measured using commercially available enzyme-linked immunosorbent assay kits. Peripheral blood samples were obtained from 10 healthy volunteers as controls. RESULTS: Mean plasma VEGF level of 41.9 pg/mL (range, 11.7–114.9 pg/mL) in patients with CCM at baseline was higher than that of the healthy controls (29.3 pg/mL, range, 9.2–64.3 pg/mL), without significant differences between CCM patients and controls (p=0.828). Plasma VEGF level following SRS dropped to 24.6 pg/mL after 1 week, and decreased to 18.5 pg/mL after 1 month, then increased to 24.3 pg/mL after 3 months, and 32.6 pg/mL after 6 months. Two patients suffering from rebleeding after SRS showed a higher level of VEGF at 6 months after SRS than their pretreatment level. CONCLUSION: Plasma VEGF levels in patients with CCM were elevated over controls at baseline, and decreased from baseline to 1 month after SRS and increased further for up to 6 months. Theses results indicated that anti-angiogenic effect of SRS might play a role in the treatment of CCMs.
